Market revenue in 2020 | USD 7.5 million |
Market revenue in 2028 | USD 17.5 million |
Growth rate | 11.2% (CAGR from 2020 to 2028) |
Largest segment | Neurological disorders |
Fastest growing segment | Cancer |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Neurological disorders was the largest segment with a revenue share of 16% in 2020. Horizon Databook has segmented the Singapore rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
Ongoing developments of diagnostics kits is expected to spur revenue growth of Singapore market. For instance, in September 2018, the KK Women’s and Children’s Hospital (KKH) has developed a test for rapid and accurate diagnosis of genetic rare diseases.
Furthermore, ongoing conferences in the country to increase awareness pertaining to management of rare disease is expected to create commercial opportunities for the market players. For instance, in February 2018, SGInnovate and Shire collectively conducted an event to share knowledge.
Horizon Databook provides a detailed overview of country-level data and insights on the Singapore rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into Singapore rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account